1. [CASE 1 — QUESTION 1]
A 67-year-old man with metastatic prostate cancer is on a stable high-dose oral morphine regimen for bone pain. Over the past 2 weeks he has had a bowel movement only every 4 to 5 days despite a scheduled regimen of polyethylene glycol and senna, with hard stools and significant straining. He has no abdominal distension, no vomiting, and passes flatus; abdominal examination is soft and nontender. Which statement best explains why his current laxative regimen has been inadequate?
A) Tolerance to polyethylene glycol develops within 2 weeks, eliminating its osmotic effect
B) Morphine inactivates senna and polyethylene glycol within the intestinal lumen
C) Opioid binding to mu-opioid receptors in the enteric plexuses reduces motility and secretion and raises sphincter tone, a receptor-mediated mechanism that osmotic and stimulant laxatives do not directly address
D) Bone metastases reduce intestinal blood flow, making any laxative ineffective
E) High-dose morphine increases colonic water secretion, which standard laxatives cannot overcome
ANSWER: C
Rationale:
Option C is correct. Opioid-induced constipation results from opioid binding to mu-opioid receptors in the myenteric and submucosal plexuses, reducing propulsive motility and secretion and increasing sphincter tone. Osmotic and stimulant laxatives do not target this receptor-mediated mechanism, so they are frequently inadequate for opioid-induced constipation.
Option A: Option A is incorrect. Polyethylene glycol does not lose its osmotic effect through tolerance over 2 weeks; the inadequacy reflects the receptor-mediated mechanism.
Option B: Option B is incorrect. Morphine does not chemically inactivate laxatives in the lumen.
Option D: Option D is incorrect. The mechanism is opioid receptor activation in the gut wall, not reduced intestinal blood flow from metastases.
Option E: Option E is incorrect. Opioids reduce intestinal secretion rather than increasing colonic water secretion.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. The team decides to add a peripherally acting mu-opioid receptor antagonist (PAMORA) to address his refractory opioid-induced constipation. Before initiating the PAMORA, which step is most important?
A) Confirm there is no known or suspected gastrointestinal obstruction, because PAMORAs are contraindicated in that setting
B) Obtain a serum magnesium level to dose the PAMORA
C) Stop the morphine for 24 hours before the first PAMORA dose
D) Administer a loading dose of loperamide to prime the gut
E) Switch all his pain control to a nonsteroidal anti-inflammatory drug first
ANSWER: A
Rationale:
Option A is correct. PAMORAs should not be given to patients with known or suspected gastrointestinal obstruction, so excluding obstruction is the essential step before initiation. His benign abdominal examination with passage of flatus supports the absence of obstruction.
Option B: Option B is incorrect. PAMORA dosing is not guided by serum magnesium.
Option C: Option C is incorrect. Stopping the needed analgesic is unnecessary and inappropriate; the PAMORA works peripherally without reversing analgesia.
Option D: Option D is incorrect. Loperamide is an antidiarrheal and would worsen constipation; it has no priming role.
Option E: Option E is incorrect. Switching to a nonsteroidal anti-inflammatory drug is not an appropriate substitute for effective cancer pain control and does not address the constipation mechanism.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. He is started on oral naloxegol with good relief. Two weeks later he develops oral candidiasis, and a clinician proposes starting oral ketoconazole. What is the most appropriate response regarding the naloxegol?
A) Continue naloxegol unchanged, as there is no interaction with ketoconazole
B) Double the naloxegol dose to overcome reduced efficacy from ketoconazole
C) Separate the naloxegol and ketoconazole doses by 2 hours to prevent gut chelation
D) Avoid the combination, because naloxegol is a CYP3A4 substrate and ketoconazole is a strong CYP3A4 inhibitor that raises naloxegol exposure and the risk of central effects, including opioid withdrawal
E) Stop the morphine instead of adjusting the naloxegol
ANSWER: D
Rationale:
Option D is correct. Naloxegol is metabolized by CYP3A4. Ketoconazole is a strong CYP3A4 inhibitor that markedly increases naloxegol concentrations, raising the risk of central nervous system exposure and opioid withdrawal; the combination is contraindicated, so an alternative antifungal should be chosen.
Option A: Option A is incorrect. There is a clinically important, contraindicated interaction between naloxegol and strong CYP3A4 inhibitors.
Option B: Option B is incorrect. Ketoconazole inhibits rather than induces CYP3A4, so naloxegol levels rise; increasing the dose worsens the risk.
Option C: Option C is incorrect. The interaction is metabolic CYP3A4 inhibition, not luminal chelation, so dose separation does not address it.
Option E: Option E is incorrect. Stopping effective analgesia is not the appropriate management; choosing a non-interacting antifungal is.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Months later he develops central nervous system metastases with radiographically confirmed blood-brain barrier disruption, and his opioid dose has been escalated substantially. Shortly after a naloxegol dose he becomes diaphoretic, anxious, and develops yawning, piloerection, and abdominal cramping. What is the best explanation and immediate action?
A) These are expected adverse effects of naloxegol that require no change
B) Blood-brain barrier disruption and the higher opioid dose can increase central nervous system exposure to the PAMORA, precipitating opioid withdrawal; the naloxegol should be discontinued
C) This is an allergic reaction to naloxegol requiring epinephrine
D) These symptoms indicate naloxegol overdose and call for activated charcoal
E) This represents progression of bowel obstruction and mandates surgery
ANSWER: B
Rationale:
Option B is correct. PAMORAs are normally excluded from the central nervous system at an intact blood-brain barrier. With barrier disruption from central nervous system metastases and a higher opioid dose, more drug can reach central receptors and precipitate opioid withdrawal, which matches his constellation of diaphoresis, anxiety, yawning, piloerection, and cramping. The naloxegol should be discontinued.
Option A: Option A is incorrect. Withdrawal signs are not expected effects to be ignored; they signal central opioid antagonism.
Option C: Option C is incorrect. The picture is opioid withdrawal, not anaphylaxis, so epinephrine is not indicated.
Option D: Option D is incorrect. The findings reflect central opioid antagonism from increased exposure, not a toxic ingestion requiring charcoal.
Option E: Option E is incorrect. These are withdrawal signs, not features of bowel obstruction.
5. [CASE 2 — QUESTION 1]
A 74-year-old woman develops profuse watery diarrhea 8 days after completing a course of ceftriaxone for pneumonia. Stool testing confirms Clostridioides difficile infection. Her white blood cell count is 21,000 cells/mcL and serum creatinine is 2.0 mg/dL, up from a baseline of 0.8 mg/dL. She is hemodynamically stable with no ileus or distension. Which oral regimen is most appropriate as initial therapy?
A) Metronidazole 500 mg three times daily
B) Fidaxomicin 200 mg twice daily, preferred because of its lower recurrence
C) Loperamide to reduce stool frequency
D) A single dose of bezlotoxumab as monotherapy
E) Oral vancomycin 125 mg four times daily, because her laboratory values meet severe CDI criteria, where vancomycin is preferred
ANSWER: E
Rationale:
Option E is correct. A white blood cell count of 15,000 or higher or a serum creatinine of 1.5 mg/dL or higher defines severe CDI; she meets both. Oral vancomycin is preferred over fidaxomicin in severe disease based on available data, with 125 mg four times daily for 10 days as a standard regimen.
Option A: Option A is incorrect. Metronidazole is no longer recommended as first-line for any CDI severity.
Option B: Option B is incorrect. Although fidaxomicin reduces recurrence in non-severe disease, vancomycin is preferred when severe criteria are met.
Option C: Option C is incorrect. Loperamide is contraindicated in CDI because of toxic megacolon risk and does not treat the infection.
Option D: Option D is incorrect. Bezlotoxumab prevents recurrence and is given with antibiotics, not as standalone treatment of active CDI.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. On hospital day 2 she becomes hypotensive with a rising lactate, marked abdominal distension, and imaging consistent with ileus. Which management approach is now most appropriate?
A) Continue standard-dose oral vancomycin 125 mg four times daily alone
B) High-dose vancomycin 500 mg four times daily by the oral or nasogastric route plus intravenous metronidazole 500 mg every 8 hours, with surgical consultation
C) Switch to oral metronidazole monotherapy
D) Add loperamide to slow stool output and reduce fluid losses
E) Begin fecal microbiota transplant emergently
ANSWER: B
Rationale:
Option B is correct. Hypotension, ileus, and distension indicate fulminant CDI. The standard approach is high-dose vancomycin 500 mg four times daily by the oral or nasogastric route combined with intravenous metronidazole 500 mg every 8 hours, with surgical consultation given the risk of toxic megacolon or perforation.
Option A: Option A is incorrect. Standard-dose oral vancomycin alone is insufficient for fulminant disease.
Option C: Option C is incorrect. Metronidazole monotherapy is inadequate; intravenous metronidazole is used as an adjunct to high-dose vancomycin here.
Option D: Option D is incorrect. Loperamide is contraindicated in CDI and is especially dangerous with ileus because of toxic megacolon risk.
Option E: Option E is incorrect. Fecal microbiota transplant is used for recurrent CDI, not as emergent therapy for fulminant acute disease.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. A covering clinician, concerned about her ongoing high-volume diarrhea and fluid losses, suggests adding loperamide to reduce stool frequency. Why is this inappropriate in her current situation?
A) Loperamide is contraindicated in CDI because suppressing the motility that helps clear toxin and organisms can precipitate toxic megacolon, a risk heightened by her existing ileus
B) Loperamide would accelerate colonic transit and worsen her diarrhea
C) Loperamide chemically inactivates oral vancomycin in the lumen
D) Loperamide is ineffective unless given intravenously
E) Loperamide is contraindicated only in children, so it would be acceptable here
ANSWER: A
Rationale:
Option A is correct. Loperamide is contraindicated in CDI because reducing propulsive motility impairs clearance of toxin and organisms and can precipitate toxic megacolon. In a patient who already has ileus and fulminant features, this danger is especially pronounced.
Option B: Option B is incorrect. Loperamide slows transit rather than accelerating it.
Option C: Option C is incorrect. Loperamide does not inactivate vancomycin; the concern is motility suppression.
Option D: Option D is incorrect. Loperamide is an oral agent; the issue is its contraindication in CDI, not the route.
Option E: Option E is incorrect. The contraindication in CDI applies to adults as well, not only children.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. She stabilizes on appropriate therapy. She is 74 years old, immunocompromised from chemotherapy, and this is a severe episode, placing her at high risk of recurrence. She has no history of heart failure. Which addition is most appropriate to reduce her recurrence risk, and what caution applies?
A) Add chronic suppressive loperamide after recovery
B) Add a prolonged second antibiotic to broaden coverage
C) Add a single intravenous infusion of bezlotoxumab during the antibiotic course; in the MODIFY 1 and MODIFY 2 trials (randomized trials showing bezlotoxumab reduced recurrent CDI versus placebo on standard antibiotics), benefit was greatest in high-risk patients, while a black box warning for heart failure exacerbation requires caution in patients with heart failure
D) Replace vancomycin with metronidazole to lower recurrence
E) Give bezlotoxumab as monotherapy without antibiotics
ANSWER: C
Rationale:
Option C is correct. Bezlotoxumab is a monoclonal antibody against toxin B given as a single intravenous infusion during antibiotic therapy to reduce recurrence. In the MODIFY 1 and MODIFY 2 trials (randomized trials showing bezlotoxumab reduced recurrent CDI versus placebo on standard antibiotics), the greatest absolute benefit was in high-risk patients such as the elderly and immunocompromised, matching her profile. It carries a black box warning for heart failure exacerbation, so caution is needed in patients with heart failure; she has none.
Option A: Option A is incorrect. Loperamide is contraindicated in CDI and does not reduce recurrence.
Option B: Option B is incorrect. A second antibiotic does not reduce recurrence and risks further microbiome disruption.
Option D: Option D is incorrect. Metronidazole is no longer first-line and would not lower recurrence relative to vancomycin.
Option E: Option E is incorrect. Bezlotoxumab is given with standard-of-care antibiotics, not as monotherapy.
9. [CASE 3 — QUESTION 1]
A 61-year-old woman was treated for a first episode of non-severe Clostridioides difficile infection with a 10-day course of oral vancomycin and improved. Three weeks later her diarrhea returns and stool testing confirms a first recurrence of CDI. She is hemodynamically stable. Which treatment is most appropriate for this first recurrence?
A) A repeat identical course of oral vancomycin 125 mg four times daily with no other change
B) Oral metronidazole 500 mg three times daily
C) Loperamide to control symptoms while observing
D) Fidaxomicin, which is preferred for a first recurrence when initial treatment was vancomycin
E) Immediate fecal microbiota transplant
ANSWER: D
Rationale:
Option D is correct. For a first recurrence when initial treatment was vancomycin, a fidaxomicin course is a preferred approach; its narrow spectrum and lower recurrence make it well suited to interrupting the recurrence cycle.
Option A: Option A is incorrect. Simply repeating an identical vancomycin course is not the preferred strategy for a first recurrence after initial vancomycin.
Option B: Option B is incorrect. Metronidazole is no longer first-line for any CDI severity, including recurrence.
Option C: Option C is incorrect. Loperamide is contraindicated in CDI and does not treat the infection.
Option E: Option E is incorrect. Fecal microbiota transplant is reserved for multiply recurrent CDI, not a first recurrence.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. She asks why fidaxomicin is expected to lower her chance of yet another recurrence compared with another vancomycin course. Which explanation is most accurate?
A) Fidaxomicin is systemically absorbed and eradicates the organism from the bloodstream
B) Fidaxomicin has a narrow spectrum that relatively spares Bacteroides and other colonization-resistance flora, whereas vancomycin suppresses them; preserving these organisms is the proposed basis for fidaxomicin's lower recurrence
C) Fidaxomicin neutralizes toxin B directly with an antibody-like action
D) Fidaxomicin permanently sterilizes the colon, preventing any recolonization
E) Fidaxomicin works only against hypervirulent NAP1 (ribotype 027) strains
ANSWER: B
Rationale:
Option B is correct. Fidaxomicin's lower recurrence is attributed to its narrow spectrum, which relatively spares Bacteroides and other colonization-resistance organisms that vancomycin suppresses. Preserving these organisms maintains colonization resistance against C. difficile.
Option A: Option A is incorrect. Fidaxomicin is minimally absorbed and acts in the colonic lumen, not the bloodstream.
Option C: Option C is incorrect. Toxin B neutralization describes the antibody bezlotoxumab, not fidaxomicin.
Option D: Option D is incorrect. Fidaxomicin does not sterilize the colon; sparing protective flora is the mechanism.
Option E: Option E is incorrect. The recurrence advantage is actually not seen with hypervirulent NAP1/ribotype 027 strains, the opposite of this claim.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. Despite the fidaxomicin course, she relapses again and over the following months experiences a total of three recurrences, each responding initially and then returning. She remains otherwise stable. Which intervention is now most appropriate to break the recurrence cycle?
A) Indefinite daily loperamide
B) Lifelong suppressive bismuth subsalicylate
C) A repeat 10-day metronidazole course
D) Switching to intravenous vancomycin for better colonic delivery
E) Fecal microbiota transplant to restore a diverse microbiome and colonization resistance
ANSWER: E
Rationale:
Option E is correct. Multiply recurrent CDI reflects persistent microbiome depletion that allows C. difficile to re-establish after each antibiotic course. Fecal microbiota transplant restores a diverse microbiome and colonization resistance, with resolution rates of roughly 80 to 90 percent, and is the preferred approach for multiply recurrent disease.
Option A: Option A is incorrect. Loperamide is contraindicated in CDI and does not address recurrence.
Option B: Option B is incorrect. Bismuth subsalicylate is not a recurrence-prevention strategy and adds a salicylate load.
Option C: Option C is incorrect. Repeating metronidazole is inappropriate; it is no longer first-line and does not break the cycle.
Option D: Option D is incorrect. Intravenous vancomycin achieves negligible colonic luminal concentrations and is ineffective for CDI.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Before proceeding, she asks how fecal microbiota transplant differs from simply giving more antibiotics, and whether there are standardized, regulated products. Which response is most accurate?
A) Fecal microbiota transplant restores the diverse microbiome that competitively excludes C. difficile, addressing the microbiome depletion that antibiotics do not repair, and standardized FDA-approved products now exist, including Rebyota and the oral capsule preparation Vowst
B) Fecal microbiota transplant delivers concentrated antibiotics directly to the colon
C) Fecal microbiota transplant supplies neutralizing antibodies against toxin B
D) There are no regulated fecal microbiota products; only unscreened donor stool can be used
E) Fecal microbiota transplant permanently sterilizes the colon to prevent recolonization
ANSWER: A
Rationale:
Option A is correct. Antibiotics treat the organism but do not repair the depleted microbiome that allows recurrence. Fecal microbiota transplant restores a diverse microbiome and the colonization resistance that competitively excludes C. difficile. Standardized, FDA-approved products now exist, including Rebyota and the oral capsule preparation Vowst, offering screened, reproducible alternatives to clinician-prepared donor stool.
Option B: Option B is incorrect. Fecal microbiota transplant restores flora; it does not deliver antibiotics.
Option C: Option C is incorrect. Antibody-based toxin B neutralization describes bezlotoxumab, not fecal microbiota transplant.
Option D: Option D is incorrect. Regulated, screened products (Rebyota, Vowst) are available, contrary to this statement.
Option E: Option E is incorrect. The goal is to restore a healthy diverse flora, not to sterilize the colon.
13. [CASE 4 — QUESTION 1]
A 36-year-old woman reports 5 months of recurrent abdominal pain occurring at least one day per week, associated with loose stools and relief of pain after defecation, with no alarm features and a normal limited workup. She meets Rome IV criteria for irritable bowel syndrome with predominant diarrhea (IBS-D). For her frequent loose stools and urgency, which agent is a reasonable first-line symptomatic choice?
A) Linaclotide to increase intestinal secretion
B) Senna to regulate her bowel habit
C) Loperamide, a peripherally selective mu-opioid agonist that slows transit and reduces stool frequency in IBS-D
D) Polyethylene glycol to soften the stool
E) Alosetron as the initial agent for all IBS-D patients
ANSWER: C
Rationale:
Option C is correct. Loperamide is a peripherally selective mu-opioid agonist that slows intestinal transit and reduces stool frequency, making it a reasonable first-line symptomatic option for the loose stools and urgency of IBS-D.
Option A: Option A is incorrect. Linaclotide increases secretion and is used for IBS-C, which would worsen diarrhea.
Option B: Option B is incorrect. Senna is a stimulant laxative and would worsen diarrhea.
Option D: Option D is incorrect. Polyethylene glycol is an osmotic laxative for constipation, inappropriate for IBS-D.
Option E: Option E is incorrect. Alosetron is restricted to women with severe IBS-D refractory to conventional therapy, not a first-line agent for all patients.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. Loperamide controls her stool frequency only partially, and bloating remains prominent. She has no constipation. A 14-day course of rifaximin is considered. Which statement best reflects its evidence-based use here?
A) Rifaximin must be taken indefinitely once started to maintain any benefit
B) Rifaximin 550 mg three times daily for 14 days is approved for IBS-D without constipation; in the TARGET 1 and TARGET 2 trials (randomized trials of rifaximin in IBS without constipation showing modest improvement in global symptoms and bloating versus placebo), responders who relapse can be retreated with similar response
C) Rifaximin is contraindicated in IBS and should not be used
D) Rifaximin is extensively absorbed and carries a high risk of systemic antibiotic resistance
E) Rifaximin should be combined with alosetron from the outset in all patients
ANSWER: B
Rationale:
Option B is correct. Rifaximin 550 mg three times daily for 14 days is approved for IBS-D without constipation. In the TARGET 1 and TARGET 2 trials (randomized trials of rifaximin in IBS without constipation showing modest but significant improvement in global symptoms and bloating versus placebo), responders who relapse can be retreated with sustained response similar to the initial course, and its minimal absorption limits systemic resistance pressure.
Option A: Option A is incorrect. Rifaximin is given as defined courses with retreatment as needed, not indefinitely.
Option C: Option C is incorrect. Rifaximin is approved and appropriate for IBS-D without constipation.
Option D: Option D is incorrect. Rifaximin is minimally absorbed, which limits systemic resistance, the opposite of this claim.
Option E: Option E is incorrect. Routine combination with alosetron is not indicated, and alosetron is restricted to severe refractory IBS-D in women.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. Her symptoms persist, and eluxadoline is considered. On review, she underwent a cholecystectomy 3 years ago. How does this surgical history affect the decision?
A) Eluxadoline is contraindicated because, without a gallbladder, its mu-opioid agonism at the sphincter of Oddi can cause sphincter spasm leading to acute pancreatitis
B) Eluxadoline requires gallbladder bile flow for activation, so it will simply be ineffective
C) Cholecystectomy increases systemic eluxadoline absorption to toxic levels
D) The surgical history is irrelevant to eluxadoline safety
E) Eluxadoline is contraindicated only in patients with an intact gallbladder
ANSWER: A
Rationale:
Option A is correct. Eluxadoline is a mixed opioid receptor modulator with mu-opioid agonism acting largely in the enteric nervous system. After cholecystectomy, loss of gallbladder regulation of bile flow allows unopposed mu-opioid agonism at the sphincter of Oddi to cause sphincter spasm and acute pancreatitis, so it is contraindicated in patients without a gallbladder.
Option B: Option B is incorrect. The danger is sphincter spasm and pancreatitis, not failed activation; eluxadoline is minimally absorbed regardless.
Option C: Option C is incorrect. The contraindication is not driven by toxic systemic absorption.
Option D: Option D is incorrect. The surgical history is decisive, as the contraindication applies specifically post-cholecystectomy.
Option E: Option E is incorrect. The contraindication applies to patients without a gallbladder, the reverse of this statement.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. Her IBS-D is now severe and debilitating, with disabling urgency and pain, and has not responded to loperamide, dietary measures, a low-dose tricyclic antidepressant, or rifaximin. Eluxadoline is contraindicated given her cholecystectomy. The gastroenterologist considers alosetron. Which statement best reflects appropriate use and counseling?
A) Alosetron can be prescribed by any clinician without restriction as a first-line agent
B) Alosetron is approved only for men with IBS-D
C) Alosetron requires no monitoring because its serious risks were disproven
D) Alosetron is available only through a Risk Evaluation and Mitigation Strategy (REMS) program for women with severe, refractory IBS-D, and she must be counseled to stop it immediately if constipation or rectal bleeding develops because of the risks of ischemic colitis and severe constipation
E) Alosetron should have been used before any other IBS-D therapy
ANSWER: D
Rationale:
Option D is correct. Alosetron, a selective 5-HT3 antagonist, is available only through a REMS program and is approved for women with severe IBS-D refractory to conventional therapy, which fits this patient. Because of the risks of ischemic colitis and severe constipation, she must be counseled to stop the drug immediately if constipation or rectal bleeding develops.
Option A: Option A is incorrect. Alosetron is restricted through a REMS program and is not an unrestricted first-line agent.
Option B: Option B is incorrect. Alosetron is approved for women with severe IBS-D, not restricted to men.
Option C: Option C is incorrect. The ischemic colitis and severe constipation risks are real and underlie the REMS program and counseling.
Option E: Option E is incorrect. Its restricted status and adverse-effect profile make it a later option after conventional therapies fail, not a first choice.
17. [CASE 5 — QUESTION 1]
A 41-year-old woman with constipation-predominant irritable bowel syndrome (IBS-C) has persistent hard stools and prominent abdominal pain despite an adequate trial of polyethylene glycol. She has no obstruction and no contraindications. Which agent best addresses both her constipation and her pain through a single mechanism?
A) Add high-dose senna for a stronger stimulant effect
B) Switch to loperamide to regulate her bowel habit
C) Start linaclotide, a guanylate cyclase-C (GC-C) agonist that raises cyclic guanosine monophosphate to drive CFTR-mediated luminal fluid secretion and also directly inhibits submucosal pain-sensing neurons
D) Begin cholestyramine to bind bile acids
E) Start alosetron under its restricted program
ANSWER: C
Rationale:
Option C is correct. Linaclotide is a GC-C agonist approved for IBS-C. By raising intracellular cyclic guanosine monophosphate, it activates CFTR-mediated chloride and bicarbonate secretion to relieve constipation and simultaneously inhibits submucosal pain-sensing neurons, addressing her pain through one mechanism. This makes it a rational escalation when an osmotic agent has been inadequate.
Option A: Option A is incorrect. Adding more stimulant laxative does not address visceral pain and is not the mechanism-based escalation for IBS-C with pain.
Option B: Option B is incorrect. Loperamide slows transit and would worsen constipation in IBS-C.
Option D: Option D is incorrect. Cholestyramine treats bile acid diarrhea, not constipation-predominant IBS.
Option E: Option E is incorrect. Alosetron is for severe IBS-D in women under a restricted program, not IBS-C.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. She tolerates linaclotide but develops loose stools, and she asks whether this is dangerous. She also mentions a young relative and asks about pediatric use. Which statement is most accurate?
A) The loose stools indicate an allergic reaction requiring immediate discontinuation and epinephrine
B) Diarrhea is the most common adverse effect and is the dose-dependent pharmacodynamic extension of the drug's secretory mechanism; additionally, linaclotide carries a black box warning against use in patients younger than 2 years because of the risk of severe secretory diarrhea and dehydration
C) Loose stools mean the drug is not working and the dose should be doubled
D) Linaclotide is safest in infants and is preferred for pediatric constipation
E) The diarrhea reflects systemic absorption causing a central effect
ANSWER: B
Rationale:
Option B is correct. Diarrhea is the most common adverse effect of linaclotide and is the dose-dependent pharmacodynamic extension of its secretory mechanism, and it is the leading reason for discontinuation. Linaclotide also carries a black box warning against use in patients younger than 2 years because severe secretory diarrhea can cause dehydration in immature gastrointestinal physiology.
Option A: Option A is incorrect. The loose stools reflect the drug's mechanism, not an allergic reaction.
Option C: Option C is incorrect. Diarrhea is an expected mechanistic effect, and doubling the dose would worsen it.
Option D: Option D is incorrect. Linaclotide is contraindicated in young children, not preferred for them.
Option E: Option E is incorrect. Linaclotide has negligible systemic absorption; the diarrhea is a local secretory effect.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. The diarrhea from linaclotide proves intolerable and it is stopped. The clinician seeks an alternative secretagogue with a different mechanism. Which agent is most appropriate, and what counseling reduces its main adverse effect?
A) Tenapanor, with counseling that it directly relieves visceral pain
B) Cholestyramine, with counseling to expect black stools
C) Senna, with counseling about cathartic colon
D) Lubiprostone, a type-2 chloride (ClC-2) channel activator; its principal adverse effect is nausea, which is reduced by taking it with food
E) Loperamide, with counseling that it increases stool frequency
ANSWER: D
Rationale:
Option D is correct. Lubiprostone activates type-2 chloride (ClC-2) channels to increase luminal fluid and is approved for chronic idiopathic constipation and IBS-C, offering a different secretagogue mechanism than the GC-C agonists. Its principal adverse effect is nausea, occurring in roughly 30 percent of patients, which is reduced by taking it with food.
Option A: Option A is incorrect. Tenapanor is an NHE3 inhibitor without a direct analgesic effect, so that counseling is inaccurate.
Option B: Option B is incorrect. Cholestyramine treats bile acid diarrhea, not IBS-C constipation, and black stools relate to bismuth.
Option C: Option C is incorrect. Senna is a stimulant laxative, not a secretagogue alternative, and cathartic colon is not substantiated.
Option E: Option E is incorrect. Loperamide slows transit and reduces stool frequency, the opposite of what is needed and stated.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. Tenapanor is raised as another option. Which statement best characterizes tenapanor relative to the guanylate cyclase-C (GC-C) agonist she previously tried?
A) Tenapanor activates type-2 chloride (ClC-2) channels, identical to lubiprostone
B) Tenapanor binds bile acids in the lumen to reduce secretion
C) Tenapanor is a mu-opioid agonist that slows transit
D) Tenapanor is extensively absorbed and acts centrally on pain pathways
E) Tenapanor inhibits the sodium/hydrogen exchanger isoform 3 (NHE3), reducing sodium and water absorption to increase luminal fluid, but unlike GC-C agonists it does not have a direct analgesic effect on intestinal nociceptors
ANSWER: E
Rationale:
Option E is correct. Tenapanor inhibits the sodium/hydrogen exchanger isoform 3 (NHE3), reducing intestinal sodium and water absorption and increasing luminal fluid to accelerate transit. Unlike GC-C agonists, it does not directly inhibit intestinal pain-sensing neurons, though relief of luminal distention may contribute to pain improvement. Its systemic bioavailability is negligible.
Option A: Option A is incorrect. ClC-2 channel activation describes lubiprostone, not tenapanor.
Option B: Option B is incorrect. Bile acid binding describes cholestyramine.
Option C: Option C is incorrect. Tenapanor is not a mu-opioid agonist.
Option D: Option D is incorrect. Tenapanor is minimally absorbed and acts locally, not centrally.
21. [CASE 6 — QUESTION 1]
A 29-year-old man develops watery diarrhea without blood or fever during international travel, consistent with traveler's diarrhea from a noninvasive enterotoxigenic Escherichia coli. He has no dysenteric features. Which agent is most appropriate, and what feature distinguishes its suitability here?
A) Rifaximin, a minimally absorbed rifamycin that achieves high intraluminal concentrations against noninvasive enteric pathogens while producing negligible systemic effect, appropriate because there are no invasive features
B) Oral vancomycin, because it is the standard for all infectious diarrhea
C) Intravenous metronidazole, because oral agents are ineffective for traveler's diarrhea
D) Linaclotide, to flush the pathogen with increased secretion
E) Cholestyramine, to bind the bacterial enterotoxin
ANSWER: A
Rationale:
Option A is correct. Rifaximin is a minimally absorbed rifamycin (less than 0.4 percent systemic bioavailability) that reaches high intraluminal concentrations against noninvasive enteric pathogens such as enterotoxigenic Escherichia coli while producing negligible systemic antibiotic effect, making it appropriate for noninvasive traveler's diarrhea. It is not suitable when invasive features (fever, dysentery) are present, which this patient lacks.
Option B: Option B is incorrect. Oral vancomycin is used for CDI, not routine traveler's diarrhea.
Option C: Option C is incorrect. Oral rifaximin is effective for noninvasive traveler's diarrhea; intravenous metronidazole is not the appropriate choice.
Option D: Option D is incorrect. Linaclotide is an IBS-C secretagogue and has no role in treating infectious diarrhea.
Option E: Option E is incorrect. Cholestyramine treats bile acid diarrhea, not enterotoxigenic traveler's diarrhea.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. He mentions that his traveling companions are also unwell and considering over-the-counter bismuth subsalicylate. One companion is a 10-year-old recovering from influenza, and another is an adult taking warfarin. Which counseling correctly applies the pharmacology of bismuth subsalicylate?
A) It is safe for both, because the salicylate is not absorbed
B) It is unsafe for both only because the bismuth ion is toxic
C) Because the salicylate component is systemically absorbed, it should be avoided in the child recovering from a viral illness due to Reye syndrome risk and used cautiously, if at all, in the adult on warfarin due to a salicylate-anticoagulant interaction
D) It is unsafe only because it turns the stool black, which could be mistaken for bleeding
E) It is contraindicated in adults but fully safe in children
ANSWER: C
Rationale:
Option C is correct. The salicylate component of bismuth subsalicylate is systemically absorbed and represents a meaningful salicylate dose. This is why it should be avoided in children and teenagers recovering from viral illness because of Reye syndrome risk and used cautiously, if at all, in patients on anticoagulants such as warfarin because of a salicylate-anticoagulant interaction.
Option A: Option A is incorrect. The salicylate is systemically absorbed, which is the basis for both cautions.
Option B: Option B is incorrect. The cautions arise from the salicylate moiety, not bismuth toxicity.
Option D: Option D is incorrect. Black discoloration is a harmless cosmetic effect, not the principal safety basis here.
Option E: Option E is incorrect. The Reye syndrome concern applies to the child, so the reasoning is reversed.
23. [CASE 6 — QUESTION 3]
Continuing with the broader differential of diarrhea, consider a separate 54-year-old patient with prior terminal ileal resection for Crohn's disease who has chronic watery diarrhea that worsens after meals and has been mislabeled as IBS-D, with standard measures failing. Which diagnosis and treatment best fit this picture?
A) Lactose intolerance, treated with a lactase supplement
B) Bile acid diarrhea from disrupted ileal bile acid reabsorption, treated with cholestyramine, a bile acid sequestrant
C) Opioid-induced constipation, treated with a peripherally acting mu-opioid antagonist
D) Clostridioides difficile infection, treated with oral vancomycin
E) Constipation-predominant IBS, treated with linaclotide
ANSWER: B
Rationale:
Option B is correct. Terminal ileal resection disrupts bile acid reabsorption, allowing excess bile acids to reach the colon and stimulate secretion and motility, a presentation often misdiagnosed as IBS-D. Cholestyramine, a bile acid sequestrant, binds the excess bile acids and treats the diarrhea.
Option A: Option A is incorrect. The ileal resection history points to bile acid diarrhea rather than lactose intolerance.
Option C: Option C is incorrect. The patient has diarrhea, not opioid-induced constipation.
Option D: Option D is incorrect. Nothing indicates CDI, and vancomycin would not treat bile acid diarrhea.
Option E: Option E is incorrect. This is a diarrheal process from bile acid malabsorption, not constipation-predominant IBS.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. He responds well to cholestyramine, but over the next month his levothyroxine becomes subtherapeutic and his warfarin effect becomes erratic. What is the best explanation and corrective step?
A) Cholestyramine is systemically absorbed and induces hepatic metabolism of both drugs, so their doses must be doubled
B) The diarrhea itself is reducing absorption, so cholestyramine should be stopped
C) Cholestyramine raises gastric pH and degrades both drugs, so an acid suppressant is needed
D) Cholestyramine binds co-administered drugs such as levothyroxine and warfarin in the gut lumen, so other medications should be taken at least 1 to 2 hours before or 4 hours after cholestyramine
E) Cholestyramine competes with both drugs for renal excretion, so fluids should be increased
ANSWER: D
Rationale:
Option D is correct. Cholestyramine is a non-absorbed anion-exchange resin that binds bile acids but also binds many co-administered drugs, including levothyroxine and warfarin, reducing their absorption. The corrective step is to separate dosing, taking other medications at least 1 to 2 hours before or 4 hours after cholestyramine, rather than stopping effective therapy.
Option A: Option A is incorrect. Cholestyramine is not absorbed and does not induce hepatic metabolism; it binds drugs in the lumen.
Option B: Option B is incorrect. The diarrhea is controlled, and the problem is luminal binding addressed by dose separation, not stopping the drug.
Option C: Option C is incorrect. Cholestyramine does not act by raising gastric pH, and an acid suppressant would not solve luminal binding.
Option E: Option E is incorrect. The interaction is luminal binding, not competition for renal excretion.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.